Athersys investor relations material

Athersys, Inc., through its subsidiary, Healios K.K., focuses on the research and development of MultiStem cell therapy to treat various diseases; and marketing and developing of MultiStem as an off-the-shelf cell therapy to treat acute myocardial infarction, acute respiratory distress syndrome, ischemic stroke, and traumatic brain injury. It also focuses on research and development activities for a range of therapeutic applications in other areas, including hematology, inflammatory bowel disease and other gastrointestinal disorders, liver disease and repair, anti-inflammation in support of wound healing applications, bone fracture repair, trauma/surgical care applications, oncology supportive care applications, diabetes mellitus, retinitis pigmentosa, and human immunodeficiency virus associated morbidities.